Who are PhaseBio Pharmaceuticals's investors?

PhaseBio Pharmaceuticals's investors include New Enterprise Associates, AstraZeneca, Hatteras Venture Partners, Johnson & Johnson Innovation, Fletcher Spaght Ventures, Cormorant Asset Management.

When was PhaseBio Pharmaceuticals founded?

PhaseBio Pharmaceuticals was founded in 2002.

Where is PhaseBio Pharmaceuticals headquartered?

PhaseBio Pharmaceuticals is headquartered in Malvern, Pennsylvania, United States.

What industry is PhaseBio Pharmaceuticals in?

PhaseBio Pharmaceuticals operates in Biotech, Drug Development.

How many employees does PhaseBio Pharmaceuticals have?

PhaseBio Pharmaceuticals has 51-200 employees.

PhaseBio Pharmaceuticals

IPO

Public · Malvern, United States · Founded 2002

Biotech

Drug Development

Headquarters: Malvern, Pennsylvania
Employees: 51–200
Founded: 2002
Business Model: B2B

Website: phasebio.com
Last Round: Series DSep 2018
Rounds: 4
Type: Public

About

PhaseBio Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapies for serious cardiovascular diseases. The company's lead program was a ticagrelor reversal agent leveraging its proprietary ELP (elastin-like polypeptide) drug delivery platform. PhaseBio filed for Chapter 11 bankruptcy protection in October 2022 after its lead cardiovascular drug candidate failed to meet its primary endpoint in a pivotal clinical trial.

Summary

PhaseBio Pharmaceuticals is a Biotech company based in Malvern, United States, founded in 2002. Its most recent funding was a Series D round in Sep 2018. Investors include New Enterprise Associates, AstraZeneca and Hatteras Venture Partners.

LinkedIn X (Twitter)